Skip to main content
Top
Published in: Diabetology International 2/2013

01-06-2013 | Original Article

Mitochondria toxicity of antihyperlipidemic agents bezafibrate and fenofibrate

Authors: K. Yamada, K. Tsunoda, K. Kawai, T. Ikeda, K. Taguchi, K. Kajita, H. Morita, T. Ishizuka

Published in: Diabetology International | Issue 2/2013

Login to get access

Abstract

Aim

Fenofibrate (FF) is known to block ATP synthesis in mitochondria by inhibiting electron transport at NADH–ubiquinone (UQ) oxidoreductase (complex I) in the respiratory chain.

Methods

Toxicity to mitochondria of bezafibrate (BF) was compared with that of FF, focusing exclusively on their effects on impairment of the electron-transport and energy-transfer systems in oxidative phosphorylation, by experiments with isolated rat liver mitochondria and submitochondrial particles (SMP).

Results

FF and BF had an uncoupling effect, enhancing ATP hydrolytic activity (latent ATPase) in mitochondria. DNP-stimulated ATPase activity was not suppressed by either agent, indicating no interference with the energy-transfer system. Both reagents inhibited NAD-linked respiration but did not affect succinate-linked respiration, indicating specific inhibition of electron-transport activity in complex I. NADH oxidase in SMP was strongly inhibited by FF, and activity was recovered by treatment with tetramethyl-p-phenylenediamine, indicating that the site of inhibition is not located at the NADH dehydrogenase portion but at the UQ site in complex I. Uncoupling and electron-transport inhibition by BF were noticeably weaker than those by FF.

Conclusions

From these results it was concluded that BF and FF were toxic to mitochondria through the dual actions of an uncoupling effect and electron-transport inhibition. The toxicity of BF to mitochondrial function was found to be noticeably weaker than that of FF, implying that BF might be much less toxic than FF for long term in-vivo use as an antihyperlipidemic agent.
Literature
1.
go back to reference Rajamani K, Colman PG, Li L-P, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC, on behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomized controlled trial. Lancet. 2009;373:1780–8.PubMedCrossRef Rajamani K, Colman PG, Li L-P, Best JD, Voysey M, D’Emden MC, Laakso M, Baker JR, Keech AC, on behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomized controlled trial. Lancet. 2009;373:1780–8.PubMedCrossRef
2.
go back to reference The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) Study. Circulation. 2000;102:21–7. The BIP study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) Study. Circulation. 2000;102:21–7.
3.
go back to reference Balfour JA, McTavish D, IIeel RC. Fenofibrate. A review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs. 1990;40:260–90.PubMedCrossRef Balfour JA, McTavish D, IIeel RC. Fenofibrate. A review of its pharmacodynamics and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs. 1990;40:260–90.PubMedCrossRef
4.
go back to reference Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care. 1988;11:495–9.PubMedCrossRef Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nambu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study. Diabetes Care. 1988;11:495–9.PubMedCrossRef
5.
go back to reference Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophs Res Commun. 2002;296:293–9.CrossRef Lee HJ, Choi SS, Park MK, An YJ, Seo SY, Kim MC, Hong SH, Hwang TH, Kang DY, Garber AJ. Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. Biochem Biophs Res Commun. 2002;296:293–9.CrossRef
6.
go back to reference Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic disease and peroxisome proliferator-activated receptors. Endocrinology. 2003;144:2201–7.PubMedCrossRef Lee CH, Olson P, Evans RM. Minireview: lipid metabolism, metabolic disease and peroxisome proliferator-activated receptors. Endocrinology. 2003;144:2201–7.PubMedCrossRef
7.
go back to reference Zou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci. 1999;48:82–9.CrossRef Zou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci. 1999;48:82–9.CrossRef
8.
go back to reference Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Werner Waldhausl W, Furnsinn C. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp. 2004;311:109–14.CrossRef Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Werner Waldhausl W, Furnsinn C. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp. 2004;311:109–14.CrossRef
9.
go back to reference Erecinska M, Wilson DF. Inhibitors of mitochondrial function. Oxford: Pergamon Press; 1981. Erecinska M, Wilson DF. Inhibitors of mitochondrial function. Oxford: Pergamon Press; 1981.
10.
go back to reference Schuneider WC. Intracellular distribution of enzymes III. The oxidation of octanoic acid by rat liver fractions. J Biol Chem. 1948;176:259–66. Schuneider WC. Intracellular distribution of enzymes III. The oxidation of octanoic acid by rat liver fractions. J Biol Chem. 1948;176:259–66.
11.
go back to reference Ruzicka HJ, Crane F. Quinone interaction with the respiratory chain-linked NADH dehydrogenase of beef heart mitochondria. I. Juglone reductase activity. Biochim Biophys Acta. 1970;223:71–85.PubMedCrossRef Ruzicka HJ, Crane F. Quinone interaction with the respiratory chain-linked NADH dehydrogenase of beef heart mitochondria. I. Juglone reductase activity. Biochim Biophys Acta. 1970;223:71–85.PubMedCrossRef
12.
go back to reference Chance B, Williams GR. Respiratory enzymes and oxidative phosphorylation. J Biol Chem. 1955;219:383–438. Chance B, Williams GR. Respiratory enzymes and oxidative phosphorylation. J Biol Chem. 1955;219:383–438.
13.
go back to reference Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;143:265–75. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;143:265–75.
14.
go back to reference Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197–202.PubMedCrossRef Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004;109:2197–202.PubMedCrossRef
15.
go back to reference Tenebaum A, Fisman EZ, Boyko V, Benderly M, Tanne d, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006;166:737–41.CrossRef Tenebaum A, Fisman EZ, Boyko V, Benderly M, Tanne d, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006;166:737–41.CrossRef
Metadata
Title
Mitochondria toxicity of antihyperlipidemic agents bezafibrate and fenofibrate
Authors
K. Yamada
K. Tsunoda
K. Kawai
T. Ikeda
K. Taguchi
K. Kajita
H. Morita
T. Ishizuka
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Diabetology International / Issue 2/2013
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-012-0104-9

Other articles of this Issue 2/2013

Diabetology International 2/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.